MariMed Holders Approve 1-for-50 to 1-for-100 Reverse Split; Board Undecided on Timing
MRMD is trading near its 52-week low of $0.05 (6.0% above the low) on light trading volume (0.4× avg).
Summary
MariMed stockholders approved a reverse split of between 1-for-50 and 1-for-100, with 219.0M votes for and 46.4M against. Whether or when to implement it remains undecided, and the Board can still abandon the split.
Key Events · Corporate Governance and Compliance · MRMD
-
Reverse Split Amendment Approved
Stockholders approved a charter amendment permitting a reverse split of not less than 1-for-50 and not more than 1-for-100, with 219,026,236 votes for, 46,400,304 against and 221,869 abstaining.
-
Board Holds Timing and Ratio Discretion
The exact ratio is left to the Board, which has not determined whether or when to effect the split and retains the right to abandon it entirely.
-
Listing Objective Behind the Split
The Board would set the final ratio based on market conditions, including potentially the requirements for a listing of the common stock on a U.S. national securities exchange; no assurance of eligibility or a sustained price increase is given.
-
Fractional Shares Paid in Cash
No fractional shares would be issued; holders entitled to a fraction would receive a cash payment in lieu, the only source of proportional-ownership change.
Analysis · MRMD · Life Sciences
The split has been on the table since the September proxy, so the news here is the margin of approval and the fact that nothing happens until the Board says so. Roughly 82% of votes cast backed the amendment (219.0M for vs 46.4M against), clearing the way for a ratio as steep as 1-for-100 — a mechanical move aimed at lifting the $0.053 share price toward the minimum needed for a U.S. national exchange listing. Existing holders keep the same proportional stake, but the Board's retained right to abandon the split means the listing path is still uncommitted. The company remains on the OTCQB with no exchange registration in place.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRMD was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $21.4M. The 52-week trading range was $0.05 to $0.16. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.